查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832196

抗肥胖治療市場（按藥物類別、給藥途徑、通路和最終用戶分類）—2025-2032 年全球預測

Anti-obesity Prescription Drugs Market by Drug Class, Administration Route, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗肥胖治療市場將成長至 127.7 億美元，複合年成長率為 8.35%。

主要市場統計數據
基準年2024年 67.1億美元
預計2025年 72.8億美元
預測年份：2032年 127.7億美元
複合年成長率（%） 8.35%

簡潔的抗肥胖療法方向以及不斷變化的臨床、商業性和管理動態，改變了相關人員的決策

在科學突破、新型給藥方式以及支付者和政策審查力度加大的推動下，處方抗肥胖藥物的治療和商業性格局正在發生重大變革時期。臨床醫師擴大將新型荷爾蒙藥物納入治療方案，與仍在服務特定患者族群的傳統藥物並存。同時，器械創新和新型口服劑型正在改變治療藥物的給藥和監測方式，為依從性干預和病人參與創造了新的接觸點。

在此背景下，從生物技術創新者到醫院系統的相關人員正在重新思考其營運假設。曾經線性的供應鏈如今面臨新的採購要求和產能壓力，競爭格局的特徵是產品快速差異化和策略聯盟的形成。臨床療效、耐受性和便利性之間不斷變化的相互作用正在重塑處方行為和醫療服務模式，這促使臨床開發、監管事務、商業團隊和分銷合作夥伴之間開展跨職能協作。

科學突破、交付創新和整合數位支援系統如何重新定義抗肥胖藥物治療的治療策略和護理途徑

近年來，科學進步已將藥物治療肥胖的模式從對症干預轉變為基於機制的生理學方法，這些方法能夠影響食慾調節、飽腹感訊號傳導和能量平衡。基於腸促胰島素的療法的出現及其臨床檢驗，加速了人們對多藥組合方案和聯合用藥策略的興趣，促使研發人員探索現有的胜肽類藥物以及靶向互補通路的下一代分子。因此，臨床試驗設計、終點選擇和長期安全性監測均已發展，以反映對持續體重管理和心臟代謝益處的期望。

同時，藥物輸送和患者體驗領域正在發生重要的創新。長效注射劑、患者友善型自動注射器和預填充注射筆以及改進的口服製劑重塑了關於依從性的討論，並帶來了新的診療點。用於依從性監測、遠端滴定和行為支持的數位化工具擴大與藥物治療相結合，透過改善療效提升了治療價值。最後，現實世界的有效性、衛生經濟學證據和病患分層是市場准入和報銷討論的核心，這些因素共同影響著處方集的部署和臨床應用軌跡。

評估近期美國關稅行動對全球供應鏈、製造決策以及處方箋抗減肥藥取得途徑的連鎖營運影響

主要經濟體的政策調整和關稅措施有可能顯著重塑全球複雜療法的供應鏈和成本結構。美國2025年的關稅環境為處方箋抗肥胖藥物的籌資策略、製造外包關係和庫存規劃帶來了新的考量。企業正在重新評估供應商集中度風險，並探索替代性生產佈局，以降低貿易政策波動帶來的風險。

這些調整會影響製造前置作業時間、品質保證監管和總到岸成本，進而影響籌資策略以及進入某些管道的商業性合理性。為此，許多相關人員正在尋求雙重採購、關鍵流程近岸外包，並與物流供應商重新協商業務條款。重要的是，法規合規性和供應鏈可追溯性是這些努力的核心，因為企業需要在成本控制與確保患者在整個分銷網路中獲得不間斷治療的需求之間取得平衡。

深入細分主導的分析，將藥物類別、劑型、配銷通路和最終用戶環境聯繫起來，為有針對性的開發和商業化策略提供資訊

了解患者群體和產品模式對於制定抗肥胖產品組合的臨床開發、商業化和分銷策略至關重要。藥物類別包括Amylin類似物（例如Pramlintide） 、GLP-1促效劑（例如度拉Dulaglutide肽、艾塞那肽、Exenatide和Semaglutide）、脂肪酶Liraglutide（例如奧利司他）以及血清素受體調變器劑（例如氯卡色林）。另一方面，口服膠囊和片劑為不願注射的患者提供了便利，並有機會在基層醫療中推廣使用。

分銷管道和終端用戶環境進一步加深了機會和風險。傳統的線下管道對於臨床監測、病患教育和低溫運輸支援仍然至關重要，而線上藥局和遠端醫療配藥則擴大了通路涵蓋範圍並提升了便利性，尤其對於慢性病管理而言。終端使用者涵蓋門診護理中心、醫院、居家照護機構和專科診所。專科診所、內分泌診所、全科醫生和減重診所都需要量身定做的支援、教育材料和臨床通訊協定。因此，商業化策略必須細緻入微，將產品屬性與用藥偏好、通路動態以及每種處方類型和護理環境的獨特需求相結合。

區域比較觀點，重點關注美洲、中東和非洲以及亞太地區的監管預期、付款人動態和分銷細微差別

區域動態以獨特的方式塑造著監管路徑、付款人互動以及更廣泛的臨床實踐生態系統。在美洲，監管機構和付款人嚴格評估長期安全性和成本效益，而醫療服務提供者網路正在迅速採用整合藥物治療和行為多模態護理模式。該地區的商業基礎設施既支援專科診所服務，也支持利用遠端醫療醫療擴大分銷，並促進了利用數位化依從性工具的靈活上市策略。

歐洲、中東和非洲呈現出差異化的監管和報銷格局，需要根據地區制定針對性的證據來產生和參與方式。許多國家高度重視嚴格的衛生經濟評估和比較有效性數據，這些數據會影響價格談判和處方取得。與當地經銷商和專科診所合作，對於應對該地區分散的配送管道通常至關重要。亞太市場成熟度參差不齊，一些國家正在推動最先進治療的快速普及，並藉助一體化的醫院體系和強大的製造能力；而另一些國家則優先考慮成本控制和國內生產。因此，供應鏈的韌性、監管協調工作以及適應當地文化的患者援助計劃是全部區域的關鍵考慮因素。

策略公司概況和聯盟架構揭示了整合開發、設備工程和數位夥伴關係關係如何塑造競爭差異化和營運彈性

競爭格局涵蓋傳統製藥商、生技藥品專家、新興生物技術創新者、設備製造商、受託製造廠商和數位健康供應商。擁有生技藥品開發、注射設備工程和低溫運輸物流綜合能力的公司在將肽基療法推向市場方面擁有獨特的營運優勢。同時，敏捷的生物技術公司正在開發新穎的作用機制和新配方，通常利用策略夥伴關係和授權協議來獲得生產規模和商業基礎設施。

供應鏈和契約製造合作夥伴在產品可用性和成本效益方面發揮著日益關鍵的作用。提供以患者為中心的自動注射器和使用者友好型注射筆的設備製造商正在提高依從性並支持醫療保健專業人員 (HCP) 的採用。提供行為指導、遠端滴定和依從性分析的數位療法供應商正成為藥物治療的重要輔助手段，使他們能夠向付款人和提供者展示價值。在整個製藥行業，從共同開發契約到分銷合作等各種合作模式對於降低上市風險和縮短時間患者獲得藥物至關重要。

製藥、製造和商業團隊的行動導向策略重點，以協調證據產生、供應彈性和付款人夥伴關係，實現永續獲取

為了保持競爭優勢，產業領導者應優先制定整合策略，將臨床定位、生產韌性和付款人參與度協調一致。首先，投資於產生超越對照試驗的可靠安全性和真實世界證據，對於支持覆蓋範圍討論和證明患者的長期獲益至關重要。在產生證據的同時，擴展設備和製劑選擇可以滿足不同的給藥偏好和依從性需求，從而擴大可覆蓋的患者群體。

在營運方面，透過地理分佈的製造、戰略契約製造夥伴關係以及增強的原料可追溯性來多元化供應鏈佈局，可以減少政策衝擊和產能限制的風險。商業團隊應部署針對特定管道的方法，將診所啟動通訊協定與遠端醫療追蹤和數位化依從性支援相結合，以最佳化醫療服務的連續性。最後，與付款人和醫療系統進行選擇性合作，制定基於結果的風險共擔協議，可以促進醫療服務的可及性，同時圍繞可衡量的臨床結果和成本補償調整獎勵。

對嚴格的多方法調查方法的透明描述，該方法結合了臨床文獻綜述、專家訪談、製造評估和數據三角測量

本研究綜合運用多種方法，將同儕審查的臨床文獻、監理備案文件、指導文件和公共聲明的結構化評審與有針對性的一手資料研究結合。與內分泌科和基層醫療的臨床醫生、監管專家、供應鏈高管、付款方和患者權益代表進行了專家諮詢，以檢驗關鍵趨勢和營運影響。製造和物流評估包括與製造外包製造商、設備供應商和低溫運輸供應商進行技術簡報，以評估產能考量和緩解策略。

本研究採用資料三角測量和交叉檢驗技術，將質性洞察與公開的臨床和監管資訊進行比對。研究應用細分映射，將藥物類別屬性與給藥方式、管道動態和最終用戶需求進行配對。品質保證方案包括專家同儕審查、跨地區評估一致性檢查以及與權威監管文件進行事實檢驗。所有主要訪談和個人化意見均遵循倫理考量和保密措施。

關於臨床創新、供應彈性和付款人參與如何融合以決定抗減肥藥的長期可及性和策略成功的綜合、封閉的觀點

處方抗減肥藥的發展軌跡由科學創新、新的交付模式以及不斷變化的政策和付款人期望決定，這些因素共同創造了機遇，也帶來了複雜性。利用生理機制的治療方法正在促使人們重新思考長期管理策略，而劑量和數位化支持的進步則拓寬了護理環境和依從性工具的頻譜。同時，監管審查和採購動態迫使企業提供更有力的現實世界證據，並設計能夠抵禦地緣政治和貿易政策動盪的彈性供應鏈。

因此，決策者必須採取整合的策略，將臨床證據、生產策略和商業性執行結合起來。這樣做將使公司能夠更好地將產品屬性與患者需求相結合，確保跨管道和跨地域的可靠獲取，並向付款人和醫療保健提供者展示其價值。未來幾年，那些將臨床可信度與營運敏捷性以及以夥伴關係主導的商業化相結合，從而確保患者永續獲得有效抗肥胖藥物的利益相關人員將獲得豐厚回報。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 肥胖併發症導致 GLP-1 受體促效劑迅速普及
  • 減少心血管事件的真實數據推動了抗肥胖藥物的廣泛採用
  • 改良的配方允許口服注射減肥藥
  • 病人依從性挑戰推動體重管理的數位健康整合
  • 保險公司根據長期醫療保健成本節省的證據擴大保險範圍
  • 針對GIP和GLP-1雙重治療途徑的競爭性藥物管線的出現

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

第 8 章：按藥物類別分類的抗肥胖藥物市場

  • Amylin 類似物
    • 普蘭林胜肽
  • GLP-1促效劑
    • Dulaglutide
    • Exenatide
    • Liraglutide
    • Semaglutide
  • 脂肪酶抑制劑
    • 奧利司他
  • 血清素受體調變器
    • 氯卡色林

9. 抗肥胖藥物市場（依給藥途徑）

  • 注射
    • 自動注射器
    • 預填充筆
    • 管瓶和注射器
  • 口服
    • 膠囊
    • 藥片

第 10 章。按分銷管道分類的抗肥胖藥物市場

  • 離線
  • 線上

第 11 章。 抗肥胖治療市場（按最終用戶）

  • 門診治療中心
  • 居家醫療
  • 醫院
  • 專科診所
    • 內分泌科診所
    • 綜合診所
    • 減重診所

第 12 章：按地區分類的減重藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 抗肥胖藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。各國抗肥胖藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Pfizer Inc.
    • AstraZeneca PLC
    • Sanofi SA
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Roche Holding AG
    • Boehringer Ingelheim International GmbH
Product Code: MRR-4358BACA7FD1

The Anti-obesity Prescription Drugs Market is projected to grow by USD 12.77 billion at a CAGR of 8.35% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.71 billion
Estimated Year [2025] USD 7.28 billion
Forecast Year [2032] USD 12.77 billion
CAGR (%) 8.35%

A concise orientation to the evolving clinical, commercial, and operational dynamics transforming prescription anti-obesity therapeutics and stakeholder decision-making

The therapeutic and commercial landscape for prescription anti-obesity drugs has entered a period of pronounced transformation driven by scientific breakthroughs, novel delivery formats, and intensified payer and policy scrutiny. Clinicians are increasingly integrating newer hormone-based agents into care pathways alongside legacy medications that continue to serve specific patient segments. Meanwhile, device innovations and novel oral formulations are changing how therapies are administered and monitored, creating fresh touchpoints for adherence interventions and patient engagement efforts.

Against this backdrop, stakeholders from biotech innovators to hospital systems must re-evaluate operational assumptions. Supply chains that were once linear are now subject to new sourcing requirements and capacity pressures, and the competitive environment is characterized by rapid product differentiation and strategic collaborations. The evolving interplay of clinical efficacy, tolerability profiles, and convenience is reshaping prescribing behavior and care delivery models, requiring cross-functional alignment between clinical development, regulatory affairs, commercial teams, and distribution partners.

How scientific breakthroughs, delivery innovations, and integrated digital support systems are collectively redefining therapeutic strategies and care pathways in anti-obesity pharmacotherapy

Recent scientific advances have shifted the paradigm of pharmacologic obesity management from symptomatic interventions to mechanistic, physiology-based approaches that impact appetite regulation, satiety signaling, and energy homeostasis. The emergence and clinical validation of incretin-based therapies have accelerated interest in multimodal regimens and combination strategies, prompting developers to explore both established peptide classes and next-generation molecules targeting complementary pathways. As a result, clinical trial design, endpoint selection, and long-term safety monitoring have all evolved to reflect expectations for sustained weight management and cardiometabolic benefit.

Concurrently, the realm of drug delivery and patient experience has seen meaningful innovation. Long-acting injectables, patient-friendly autoinjectors and prefilled pens, and improved oral formulations have reframed adherence conversations and enabled new points of care. Digital tools for adherence monitoring, remote titration, and behavioral support are increasingly integrated with pharmacotherapy, reinforcing therapeutic value through improved outcomes. Finally, market access and reimbursement dialogues now center on real-world effectiveness, health-economic evidence, and patient stratification, which together influence formulary placement and clinical adoption trajectories.

Assessment of the cascading operational consequences of recent United States tariff measures on global supply chains, manufacturing decisions, and access pathways for prescription anti-obesity therapeutics

Policy adjustments and tariff actions in major economies can materially reconfigure global supply chains and cost structures for complex therapeutics, particularly when active pharmaceutical ingredients, biologics manufacturing inputs, and finished-dose forms cross multiple borders during production. The 2025 tariff environment in the United States has introduced new considerations for sourcing strategies, contract manufacturing relationships, and inventory planning for prescription anti-obesity products. Companies are reassessing supplier concentration risks and exploring alternative manufacturing footprints to mitigate exposure to trade-policy volatility.

This recalibration has implications for manufacturing lead times, quality assurance oversight, and total landed costs, which in turn affect procurement strategies and the commercial calculus for entry into specific channels. In response, many stakeholders are pursuing dual-sourcing arrangements, nearshoring of critical processes, and renegotiation of commercial terms with logistics providers. Importantly, regulatory compliance and supply-chain traceability have become central to these efforts, as firms balance cost containment with the necessity of maintaining uninterrupted patient access to therapies across distribution networks.

Deep segmentation-driven analysis linking drug classes, administration formats, distribution channels, and end-user environments to inform precise development and commercialization tactics

Understanding patient segments and product modalities is essential to tailoring clinical development, commercialization, and distribution strategies across the anti-obesity portfolio. Drug classes span amylin analogs such as pramlintide, a range of GLP-1 agonists including dulaglutide, exenatide, liraglutide, and semaglutide, lipase inhibitors exemplified by orlistat, and serotonin receptor modulators like lorcaserin; each class presents distinct efficacy, safety, and tolerability profiles that inform positioning and prescriber choice. Moreover, formulation and administration route drive differential adoption patterns: injectables delivered via autoinjectors, prefilled pens, and traditional vial-and-syringe formats attract patients and providers seeking longer-acting or titratable therapies, while oral capsules and tablets offer convenience for those averse to injections and opportunities for primary care adoption.

Distribution channels and end-user settings further stratify opportunity and risk. Traditional offline channels remain important for clinical oversight, patient education, and cold-chain handling, while online pharmacies and telehealth-enabled dispensing expand access and convenience, particularly for chronic management. End users range from ambulatory care centers and hospitals to home-care settings and specialty clinics; within specialty clinics, endocrinology practices, general practice clinics, and weight-loss clinics each demand tailored support, educational materials, and clinical protocols. Therefore, commercialization strategies must be nuanced, aligning product attributes with administration preferences, channel dynamics, and the specific needs of prescriber types and care settings.

Comparative regional perspectives highlighting regulatory expectations, payer dynamics, and distribution nuances across the Americas; Europe, Middle East & Africa; and Asia-Pacific territories

Regional dynamics shape regulatory pathways, payor interactions, and the broader ecosystem of clinical practice in distinctive ways. In the Americas, regulatory agencies and payers are closely evaluating long-term safety and cost effectiveness, while provider networks are rapidly adopting multimodal care models that integrate pharmacotherapy with behavioral interventions. The commercial infrastructure in this region supports both specialty clinic delivery and expanding telehealth-enabled distribution, encouraging flexible launch strategies that leverage digital adherence tools.

Europe, the Middle East & Africa present heterogeneous regulatory and reimbursement landscapes that require localized evidence generation and engagement approaches. Many countries emphasize rigorous health-economic assessments and comparative effectiveness data, which influences pricing negotiations and formulary access. In this region, partnerships with regional distributors and specialized clinics are often essential to navigate fragmented delivery channels. Asia-Pacific markets exhibit diverse maturity levels; some countries are advancing rapid uptake of cutting-edge therapies supported by integrated hospital systems and strong manufacturing capabilities, while others are prioritizing cost containment and domestic production. Supply-chain resilience, regulatory harmonization efforts, and culturally adapted patient-support programs are therefore critical considerations across these geographies.

Strategic company profiles and alliance architectures that reveal how integrated development, device engineering, and digital partnerships are shaping competitive differentiation and operational resilience

The competitive landscape encompasses legacy pharmaceutical manufacturers, biologics specialists, emerging biotech innovators, device makers, contract manufacturing organizations, and digital health vendors. Firms with integrated capabilities across biologics development, device engineering for injectables, and cold-chain logistics possess distinct operational advantages when bringing peptide-based therapies to market. Simultaneously, agile biotech companies are advancing novel mechanisms of action and new formulations, often leveraging strategic partnerships or licensing deals to access manufacturing scale and commercial infrastructure.

Supply-chain and contract manufacturing partners are increasingly visible as pivotal contributors to product availability and cost efficiency. Device manufacturers that can deliver patient-centered autoinjectors and user-friendly pens enhance adherence and support provider uptake. Digital therapeutics vendors offering behavioral coaching, remote titration, and adherence analytics are becoming important adjuncts to pharmacotherapy, enabling value demonstrations to payers and providers. Across the sector, collaborative models-ranging from co-development agreements to distribution partnerships-are central to de-risking launches and accelerating time to patient access.

Action-oriented strategic priorities for pharmaceutical, manufacturing, and commercial teams to align evidence generation, supply resilience, and payer partnerships for sustained access

Industry leaders should prioritize integrated strategies that align clinical positioning, manufacturing resilience, and payer engagement to sustain competitive advantage. First, investing in robust safety and real-world evidence generation that extends beyond controlled trials will be essential to support coverage conversations and demonstrate long-term patient benefit. Parallel to evidence generation, expanding device and formulation options can broaden the addressable patient base by meeting diverse administration preferences and adherence needs.

Operationally, diversifying supply-chain footprints via geographically distributed manufacturing, strategic contract manufacturing partnerships, and enhanced raw-material traceability will reduce exposure to policy shocks and capacity constraints. Commercial teams should deploy channel-specific approaches that integrate in-clinic initiation protocols with telehealth follow-up and digital adherence supports to optimize continuity of care. Finally, pursuing selective collaborations with payers and health systems to develop outcomes-based contracts or risk-sharing agreements can facilitate access while aligning incentives around measurable clinical outcomes and cost offsets.

Transparent description of the rigorous multi-method research approach combining clinical literature review, expert interviews, manufacturing assessments, and data triangulation

This research synthesizes a multi-method approach combining a structured review of peer-reviewed clinical literature, regulatory filings, guidance documents, and public policy statements with targeted primary research. Expert consultations were conducted with clinicians across endocrinology and primary care, regulatory specialists, supply-chain executives, payers, and patient advocacy representatives to validate key trends and operational implications. Manufacturing and logistics assessments drew on technical briefings with contract manufacturers, device suppliers, and cold-chain providers to assess capacity considerations and mitigation strategies.

Data triangulation and cross-validation techniques were used to reconcile qualitative insights with publicly available clinical and regulatory information. The study applied segmentation mapping to align drug-class attributes with delivery modalities, channel dynamics, and end-user needs. Quality assurance protocols included peer review by subject-matter experts, consistency checks across regional assessments, and verification of factual statements against authoritative regulatory documents. Ethical considerations and confidentiality safeguards were maintained for all primary interviews and proprietary inputs.

A synthesized closing perspective on how clinical innovation, supply resilience, and payer engagement converge to determine long-term access and strategic success in anti-obesity therapeutics

The trajectory of prescription anti-obesity therapeutics is defined by scientific innovation, new delivery models, and shifting policy and payer expectations that together create both opportunity and complexity. Emerging therapies that leverage physiologic mechanisms have catalyzed rethinking of long-term management strategies, while advances in administration and digital support expand the spectrum of care settings and adherence tools. At the same time, regulatory scrutiny and procurement dynamics are compelling firms to produce stronger real-world evidence and to design resilient supply chains that can withstand geopolitical and trade-policy disruptions.

Decision-makers must therefore adopt integrated playbooks that bring clinical evidence, manufacturing strategy, and commercial execution into alignment. By doing so, organizations can better match product attributes to patient needs, secure reliable access across channels and geographies, and demonstrate value to payers and providers. The coming years will reward stakeholders who combine clinical credibility with operational agility and partnership-driven commercialization, enabling sustainable patient access to effective anti-obesity pharmacotherapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of GLP-1 receptor agonists driven by obesity comorbidity outcomes
  • 5.2. Real-world cardiovascular event reduction data boosting anti-obesity drug uptake
  • 5.3. Formulation improvements enabling oral administration of injectable obesity therapies
  • 5.4. Patient adherence challenges prompting digital health integration for weight management
  • 5.5. Payers expanding coverage policies in response to long-term health cost savings evidence
  • 5.6. Emerging competitive pipeline drugs targeting dual GIP and GLP-1 therapeutic pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-obesity Prescription Drugs Market, by Drug Class

  • 8.1. Amylin Analogs
    • 8.1.1. Pramlintide
  • 8.2. GLP-1 Agonists
    • 8.2.1. Dulaglutide
    • 8.2.2. Exenatide
    • 8.2.3. Liraglutide
    • 8.2.4. Semaglutide
  • 8.3. Lipase Inhibitors
    • 8.3.1. Orlistat
  • 8.4. Serotonin Receptor Modulators
    • 8.4.1. Locaserin

9. Anti-obesity Prescription Drugs Market, by Administration Route

  • 9.1. Injectables
    • 9.1.1. Auto-Injectors
    • 9.1.2. Prefilled Pens
    • 9.1.3. Vials And Syringes
  • 9.2. Orals
    • 9.2.1. Capsules
    • 9.2.2. Tablets

10. Anti-obesity Prescription Drugs Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Anti-obesity Prescription Drugs Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Care Settings
  • 11.3. Hospitals
  • 11.4. Specialty Clinics
    • 11.4.1. Endocrinology Clinics
    • 11.4.2. General Practice Clinics
    • 11.4.3. Weight Loss Clinics

12. Anti-obesity Prescription Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-obesity Prescription Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-obesity Prescription Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Novo Nordisk A/S
    • 15.3.2. Eli Lilly and Company
    • 15.3.3. Pfizer Inc.
    • 15.3.4. AstraZeneca PLC
    • 15.3.5. Sanofi S.A.
    • 15.3.6. GlaxoSmithKline plc
    • 15.3.7. Johnson & Johnson
    • 15.3.8. Merck & Co., Inc.
    • 15.3.9. Roche Holding AG
    • 15.3.10. Boehringer Ingelheim International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 287. EUR